Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis
Husam Ghanim, Sanaa Abuaysheh, Jeanne Hejna, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 4, pp. e1056-e1063
Open Access | Times Cited: 154

Showing 26-50 of 154 citing articles:

Dapagliflozin and Anemia in Patients with Chronic Kidney Disease
Akihiko Koshino, Meir Schechter, Glenn M. Chertow, et al.
NEJM Evidence (2023) Vol. 2, Iss. 6
Open Access | Times Cited: 34
Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench
Xin Chen, Carl‐Friedrich Hocher, Linghong Shen, et al.
AJP Cell Physiology (2023) Vol. 325, Iss. 3, pp. C661-C681
Closed Access | Times Cited: 32
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management
Naseema Gangat, Natasha Szuber, Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 6, pp. 965-981
Open Access | Times Cited: 29
Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure
Christiane E. Angermann, Carlos G. Santos‐Gallego, Juan Antonio Requena-Ibáñez, et al.
Nature Cardiovascular Research (2023) Vol. 2, Iss. 11, pp. 1032-1043
Open Access | Times Cited: 29
Anemia Management in the Cardiorenal Patient: A Nephrological Perspective
María Marqués, José Pórtoles, Marta Cobo Marcos, et al.
Journal of the American Heart Association (2025) Vol. 14, Iss. 5
Open Access | Times Cited: 1
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond
Massimiliano Camilli, Marcello Viscovo, Luca Maggio, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 8
Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy
Marianela Iriarte‐Gahete, Laura Tarancón‐Díez, Vanesa Garrido‐Rodríguez, et al.
Blood Reviews (2024) Vol. 68, pp. 101227-101227
Closed Access | Times Cited: 8
Erythrocytosis and CKD: A Review
Mabel Aoun, Michel Jadoul, Hans‐Joachim Anders
American Journal of Kidney Diseases (2024) Vol. 84, Iss. 4, pp. 495-506
Open Access | Times Cited: 7
Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
Ele Ferrannini, Ashwin Murthy, Yong‐ho Lee, et al.
Diabetes Care (2020) Vol. 43, Iss. 9, pp. 2183-2189
Open Access | Times Cited: 46
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study
Mikhail Kosiborod, Otávio Berwanger, Gary G. Koch, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 4, pp. 886-896
Open Access | Times Cited: 45
Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes
Katerina Marathias, Vaia Lambadiari, Konstantinos Markakis, et al.
American Journal of Nephrology (2020) Vol. 51, Iss. 5, pp. 349-356
Open Access | Times Cited: 40
Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis
Mehmet Kanbay, Laura Țăpoi, Carina Ureche, et al.
International Urology and Nephrology (2021) Vol. 54, Iss. 4, pp. 827-841
Closed Access | Times Cited: 37
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
David Z.I. Cherney, Jacob A. Udell, Daniel J. Drucker
Med (2021) Vol. 2, Iss. 11, pp. 1203-1230
Open Access | Times Cited: 36
Role of abnormal energy metabolism in the progression of chronic kidney disease and drug intervention
Xuyan Liu, Huasheng Du, Yan Sun, et al.
Renal Failure (2022) Vol. 44, Iss. 1, pp. 790-805
Open Access | Times Cited: 25
Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
Hiroki Akiyama, Akihiro Nishimura, Naru Morita, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 16
An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
Dóra Balogh, László Wagner, Andrea Fekete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7789-7789
Open Access | Times Cited: 15
Phase angle and extracellular water-to-total body water ratio estimated by bioelectrical impedance analysis are associated with levels of hemoglobin and hematocrit in patients with diabetes
Taiki Hori, Shingen Nakamura, Hiroki Yamagami, et al.
Heliyon (2023) Vol. 9, Iss. 4, pp. e14724-e14724
Open Access | Times Cited: 14
Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases
Naseema Gangat, Mostafa Abdallah, Natasha Szuber, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 7
Open Access | Times Cited: 14
Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review
Rosalinda Madonna, Filippo Biondi, Mattia Alberti, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116650-116650
Open Access | Times Cited: 5
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
Claire L. Vale, Peter J. Godolphin, David J. Fisher, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 10, pp. 735-747
Open Access | Times Cited: 5
Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial
Christiane E. Angermann, Susanne Sehner, Louisa M.S. Gerhardt, et al.
European Heart Journal (2024)
Open Access | Times Cited: 5
Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
Jens Aberle, Markus Menzen, Sebastian Schmid, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 38
Correction of anemia by dapagliflozin in patients with type 2 diabetes
Bergur V. Stefánsson, Hiddo J.L. Heerspink, David C. Wheeler, et al.
Journal of Diabetes and its Complications (2020) Vol. 34, Iss. 12, pp. 107729-107729
Open Access | Times Cited: 36
Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta‐analysis
Qi Tian, Keyu Guo, Jiayi Deng, et al.
Journal of Cellular and Molecular Medicine (2021) Vol. 26, Iss. 2, pp. 540-547
Open Access | Times Cited: 28
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Subodh Verma, Sunder Mudaliar, Peter J. Greasley
Advances in Therapy (2023) Vol. 41, Iss. 1, pp. 92-112
Open Access | Times Cited: 13

Scroll to top